

# CareConnect 6.0 Release – July 28<sup>th</sup>, 2021





## Immunizations - Update

1. <u>Comments – new!</u>

A new **Comments** column has been added to the *Immunizations History* table to signify that a specific agent has additional annotations that may contain clinically relevant information. To view, simply click on the row where the *Comments* column has this icon F displayed.

#### 2. <u>Alerts</u> – *new!*

An **Alert** icon **II** has been added to the *Immunizations History* table to signify that an alert was associated with an immunization. This icon will be displayed for any immunizations that have an *Adverse Event*.

ENCOUNTERS   LABS   ABS   IMAUNIZATION HISTORY      INAGING   INAGING   COVID-19 mRNA   Diphtheria(1), Haemophilus Influenzae Type b (Hibl(2), Pertussis(2), Polo(2), Telanus(3)   2003 JUL 24	ORY         Corr         Corr         Lial Immunization Registry record ONLY. Immunization history displayed may not portray the client's complete immunization history and should not be used as proof of immunization.         ANTIGEN (DOSE)       DATE ADMINISTERED       Volume       TRADE NAME       LOT #       COMMENT         COVID-19(1)       2021 MAR 06       0.3 mL       Pfizer mRNA BNT162b2       EL0203       EL0204       EL0204       EL0204 <th></th> <th></th> <th></th> <th></th> <th>Search by: PHN</th> <th>~</th> <th>Search GO</th> <th>MY PATIENTS</th> <th>MESSAGE</th>					Search by: PHN	~	Search GO	MY PATIENTS	MESSAGE
SUMMARY       Immunizations       What's Available       Principal         ENCOUNTERS       Immunization HISTORY       Immunization Registry record ONLY. Immunization history displayed may not portray the clent's complete limmunization history and should not be used as proof of Immunization history displayed may not portray the clent's complete limmunization history and should not be used as proof of Immunization for the clent's complete limmunization history and should not be used as proof of Immunization for the clent's complete limmunization history and should not be used as proof of Immunization for the clent's complete limmunization history and should not be used as proof of Immunization for the clent's complete limmunization history and should not be used as proof of Immunization for the clent's complete limmunization history and should not be used as proof of Immunization for the clent's complete limmunization history and should not be used as proof of Immunization for the clent's complete limmunization history and should not be used as proof of Immunization for the used (CVID-19 mRNA COVID-19 (f))       Antiger (DOSE)       Date Administered       Volume       Trade NAME       LOT #       LOT #         MEDICATIONS       COVID-19 mRNA       COVID-19 (f)       COVID-19       2021 MAR 03 (OX)       0.1 mL       Pfizer mRNA BNT f62b2       Ek4245         DIap-IPV-Hib       Diphthenia(1), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polo(2), Tetanus(2)       2002 MAY 03       Immunization for the complete influenzae Type b (Hib)(2), Pertussis(2), Polo(2), Tetanus(3)       2003 JUL 24	DATE ADMINISTERED       VOLUME       TRADE NAME       LOT #       COMMENT         ANTIGEN (DOSE)       DATE ADMINISTERED       VOLUME       TRADE NAME       LOT #       COMMENT         COVID-19(1)       2021 MAR 06       0.3 mL       Pfizer mRNA BNT162b2       EL0203       Image: COVID-19       2021 MAR 03 (QX)       0.1 mL       Pfizer mRNA BNT162b2       EK4245       Image: COVID-19       2021 MAR 03 (QX)       0.1 mL       Pfizer mRNA BNT162b2       EK4245       Image: COVID-19       2021 MAR 03 (QX)       0.1 mL       Pfizer mRNA BNT162b2       EK4245       Image: COVID-19       2021 MAR 03 (QX)       0.1 mL       Pfizer mRNA BNT162b2       EK4245       Image: COVID-19       2021 MAR 03 (QX)       0.1 mL       Pfizer mRNA BNT162b2       EK4245       Image: COVID-19       2021 MAR 03 (QX)       0.1 mL       Pfizer mRNA BNT162b2       EK4245       Image: COVID-19       2021 MAR 03 (QX)       0.1 mL       Pfizer mRNA BNT162b2       EK4245       Image: COVID-19       2021 MAR 03 (QX)       0.1 mL       Pfizer mRNA BNT162b2       EK4245       Image: COVID-19       2021 MAR 03 (QX)       0.1 mL       Pfizer mRNA BNT162b2       EK4245       Image: COVID-19       2021 MAR 03		«	-	· · · · · · · · · · · · · · · · · · ·					
LABS       A       Disclaimen: Provincial Immunization Registry record ONLY. Immunization history displayed may not portray the client's complete immunization history and should not be used as proof of Immunization Registry record ONLY. Immunization history displayed may not portray the client's complete immunization history and should not be used as proof of Immunization Registry record ONLY. Immunization history displayed may not portray the client's complete immunization history and should not be used as proof of Immunization Registry record ONLY. Immunization Registry record ONLY. Immunization Registry record ONLY. Immunization history displayed may not portray the client's complete immunization history and should not be used as proof of Immunization Registry record ONLY. Immunizatin Registry record ONLY. Immunization Registry	AntiGEN (DOSE)       DATE ADMINISTERED       VOLUME       TRADE NAME       LOT #       COMMENT         COVID-19(1)       2021 MAR 06       0.3 mL       Pfizer mRNA BNT162b2       EL0203       EL0203       EL425		:	💉 immunizatio	NS			Wha	t's Available	Print 🕞
LABS       A       AGENT       ANTIGEN (DOSE)       DATE ADMINISTERED       VOLUME       TRADE NAME       LOT #         IMAGING       Image: Covid-19 mRNA       COVID-19(1)       2021 MAR 06       0.3 mL       Pfizer mRNA BNT162b2       EL0203         IEDICATIONS       COVID-19 mRNA       COVID-19       COVID-19       2021 MAR 03 (OX)       0.1 mL       Pfizer mRNA BNT162b2       EK4245         DOCUMENTS       Image: Covid-19       Diphtheria(1). Haemophilus Influenzae Type b (Hib)(2). Perfussis(2). Polio(2). Tetanus(2)       2002 MAY 03       Image: Covid-19	ANTIGEN (DOSE)     DATE ADMINISTERED     VOLUME     TRADE NAME     LOT #     COMMENT       COVID-19(1)     2021 MAR 06     0.3 mL     Pfizer mRNA BNT162b2     EL0203       COVID-19     2021 MAR 03 (QX)     0.1 mL     Pfizer mRNA BNT162b2     EK4245       Uphtheria(1), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polio(2), Tetanus(2)     2002 MAY 03     EK4245     EK4245       Diphtheria(3), Haemophilus Influenzae Type b (Hib)(3), Pertussis(3), Polio(3), Tetanus(3)     2003 JUL 24     EK4245     EK4245       Altert     2016 DEC 20     EK4245     EK4245     EK4245	NCOUNTERS	ŝ	IMMUNIZATION HIS	STORY					
IMAGING         COVID-19 mRNA         COVID-19(1)         2021 MAR 06         0.3 mL         Pfizer mRNA BNT162b2         EL0203           EDICATIONS         COVID-19 mRN         COVID-19         2021 MAR 03 (02X)         0.1 mL         Pfizer mRNA BNT162b2         EK4245           DOCUMENTS         DTaP-IPV-Hit         Diphtheria(1), Haemophilus Influenzae Type b (Hib)(1), Pertussis(1), Polio(1), Tetanus(1)         2001 SEP 27             COMMUNITY         Diphtheria(3), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polio(2), Tetanus(2)         2002 MAY 03	COVID-19(1)         2021 MAR 06         0.3 mL         Pfizer mRNA BNT 162b2         EL0203           COVID-19         2021 MAR 03 (QX)         0.1 mL         Pfizer mRNA BNT 162b2         EK4245           Iphtheria(1). Haemophilus Influenzae Type b (Hib)(2). Pertussis(2). Polio(2). Tetanus(2)         2001 SEP 27         Image: Covid And C	LABS	Å	DISCLAIMER: Provi	ncial Immunization Registry record ONLY. Immunization history displayed may not port	tray the client's complete imm	nunization his	tory and should not be use	d as proof of imm	nunization.
COVID-19 mRNA         COVID-19(1)         2021 MAR 06         0.3 mL         Pfizer mRNA BNT162b2         EL0203           LEDICATIONS         COVID-19 mRNA         COVID-19(1)         2021 MAR 03 (02)         0.1 mL         Pfizer mRNA BNT162b2         EK4245           DOCUMENTS         DTaP-IPV-Hite         Diphtheria(1), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polio(2), Tetanus(2)         2002 MAY 03              COMMUNITY         DTaP-IPV-Hite         Diphtheria(3), Haemophilus Influenzae Type b (Hib)(2), Pertussis(3), Polio(3), Tetanus(2)         2002 MAY 03	COVID-19       2021 MAR 03 (0X)       0.1 mL       Pfizer mRNA BNT 162b2       EK4245         Uphtheria(1), Haemophilus Influenzae Type b (Hib)(1), Pertussis(1), Polio(1), Tetanus(1)       2001 SEP 27       2002 MAY 03       2002 MAY 03         Diphtheria(3), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polio(2), Tetanus(2)       2002 MAY 03       2003 JUL 24       Comment         Diphtheria(3), Haemophilus Influenzae Type b (Hib)(3), Pertussis(3), Polio(3), Tetanus(3)       2003 JUL 24       Comment         Alert       2016 DEC 20       2016 DEC 20       2016 DEC 20									
DDP-IPV-Hit         Uphtheria(1), Haemophilus Influenzae Type b (Hib)(1), Pertussis(1), Polio(1), Tetanus(1)         2001 SEP 27           DTaP-IPV-Hit         Diphtheria(2), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polio(2), Tetanus(2)         2002 MAY 03           COMMUNITY         DTaP-IPV-Hit         Diphtheria(3), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polio(2), Tetanus(2)         2002 MAY 03	I phtheria(1), Haemophilus Influenzae Type b (Hib)(1), Pertussis(1), Polio(1), Tetanus(1)       2001 SEP 27         Diphtheria(2), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polio(2), Tetanus(2)       2002 MAY 03         Diphtheria(3), Haemophilus Influenzae Type b (Hib)(3), Pertussis(3), Polio(3), Tetanus(3)       2003 JUL 24         2012 MAR 13       2012 MAR 13         Alert       2016 DEC 20	IMAGING	6%	AGENT	ANTIGEN (DOSE)	DATE ADMINISTERED	VOLUME	TRADE NAME	LOT #	COMMENT
DOCUMENTS         DTaP-IPV-HIb         Diphtheria(2), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polio(2), Tetanus(2)         2002 MAY 03           COMMUNITY         DTaP-IPV-Hib         Diphtheria(3), Haemophilus Influenzae Type b (Hib)(3), Pertussis(3), Polio(3), Tetanus(3)         2003 JUL 24	Diphtheria(2), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polio(2), Tetanus(2) 2002 MAY 03 Diphtheria(3), Haemophilus Influenzae Type b (Hib)(3), Pertussis(3), Polio(3), Tetanus(3) 2003 JUL 24 2012 MAR 13 2016 DEC 20 Comment	IMAGING	øb							COMMENT
COMMUNITY DIaP-IPV-Hib Diphtheria(2), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polio(2), Tetanus(2) 2002 MAY 03	Diphtheria(3), Haemophilus Influenzae Type b (Hib)(3), Pertussis(3), Polio(3), Tetanus(3)     2003 JUL 24       Comment       Alert			COVID-19 mRNA	COVID-19(1)	2021 MAR 06	0.3 mL	Pfizer mRNA BNT162b2	EL0203	$\cap$
DiaP-IPV-Flip DiaP-IPV-Flip Diaphilitation (3), Flat Flat (3),	Alert 2012 MAR 13 2016 DEC 20	EDICATIONS	4	COVID-19 mRNA COVID-19 mRNA	COVID-19(1) COVID-19	2021 MAR 06 2021 MAR 03 ( <u>OX)</u>	0.3 mL	Pfizer mRNA BNT162b2	EL0203	$\cap$
	2016 DEC 20	EDICATIONS DOCUMENTS	<b>→</b>	COVID-19 mRNA COVID-19 mRN DTaP-IPV-Hit	COVID-19(1) COVID-19 Uphtheria(1), Haemophilus Influenzae Type b (Hib)(1), Pertussis(1), Polio(1), Tetanus(1)	2021 MAR 06 2021 MAR 03 ( <u>0X</u> ) 2001 SEP 27	0.3 mL	Pfizer mRNA BNT162b2	EL0203	$\cap$
		EDICATIONS DOCUMENTS COMMUNITY	-	COVID-19 mRNA COVID-19 mRNA DTaP-IPV-Hit DTaP-IPV-Hit	COVID-19(1) COVID-19 Uphtheria(1), Haemophilus Influenzae Type b (Hib)(1), Pertussis(1), Polio(1), Tetanus(1) Diphtheria(2), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polio(2), Tetanus(2)	2021 MAR 06 2021 MAR 03 (OX) 2001 SEP 27 2002 MAY 03	0.3 mL	Pfizer mRNA BNT162b2 Pfizer mRNA BNT162b2	EL0203 EK4245	$\cap$
UNIZATIONS 🥕 HA Alert 2016 DEC 20	2001 SED 27 (E)	EDICATIONS DOCUMENTS COMMUNITY DOCUMENTS		COVID-19 mRNA COVID-19 mRNA DTaP-IPV-Hib DTaP-IPV-Hib DTaP-IPV-Hib HA	COVID-19(1) COVID-19(1) Dohtheria(1), Haemophilus Influenzae Type b (Hib)(1), Pertussis(1), Polio(1), Tetanus(1) Diphtheria(2), Haemophilus Influenzae Type b (Hib)(2), Pertussis(2), Polio(2), Tetanus(2) Diphtheria(3), Haemophilus Influenzae Type b (Hib)(3), Pertussis(3), Polio(3), Tetanus(3)	2021 MAR 06 2021 MAR 03 (OX) 2001 SEP 27 2002 MAY 03 2003 JUL 24	0.3 mL	Pfizer mRNA BNT162b2 Pfizer mRNA BNT162b2	EL0203 EK4245	$\cap$

Aanagement / Information Technology Services, PHSA ealth Authorities and the BC Ministry of Health

BRITISHA Ministry of Haldh





mits







#### 3. Immunizations Details Page – new!

The new **Immunizations Details** page provides a comprehensive clinical picture associated with a patient's immunization. It includes detailed information related to the immunization and any associated comments and/or alerts.

AGENT DETAILS - COV	(ID-19 mRNA - 2021 M	1AR 03						?
Agent:	COVID-19	mRNA			Volume:	0.1 mL		
Date Administered:	2021 MAR	03			Trade Name:	Pfizer m	nRNA BNT162b2	
Agent Status:	Invalid (ove	erride)			Lot #:	EK4245	5	
Notes:			ion has been overridden.		Yukon recommended/routine schedule	-		
							Immunization Details	
ANTIGEN STATUS						<		
ANTIGEN		DOSE NUMBER		STATUS				
COVID-19				Invalid (override)				
ADVERSE EVENTS FOLLOW	ING IMMUNIZATION							
DATE REPORTED:	2001 OCT 01							
STATUS:	Submitted for review	/		Aler	t for Adverse E	vent		
AGENT (DATE ADMINISTERED):	COVID-19 mRNA	4						
RECOMMENDATION DATE	PUBLIC HEALTH REC	COMMENDATION	COMMENTS					
2001 OCT 10	No change to immur	nization schedule	reaction does not war	rant change in schedule.				
2001 OCT 12	Controlled setting fo	r next immunization						
VACCINE AND DOSE REVISI	ON COMMENTS							
2021 MAR 03 - 07:55 AM - RE	ECORDED BY: PHIXS	SYSTEM				_		
ANTIGENS:	All				Comm	ents		
COMMENTS:			5df-4380-a8d6-e60fd10t nt pulled away arm. Con		Given By Client. Recorded by BCY_eF	orm: Peter P	Pan: 604-123-4567 Email: peter.pan@vch.ca	

### 3. <u>Renamed Column Headers</u> – updated!

Column headers within the Immunizations tab have been revised.

Previous Headers	New Headers
Immunization	Agent
Description (Dose)	Antigen (Dose)
	Date Administered
Dosage	Volume

#### For questions, email: <u>CareConnect@phsa.ca</u>

ation Management / Information Technology Services, PHSA g BC Health Authorities and the BC Ministry of Health











